[go: up one dir, main page]

WO2008131364A3 - Methods of diagnosing alzheimer's disease and associated markers - Google Patents

Methods of diagnosing alzheimer's disease and associated markers Download PDF

Info

Publication number
WO2008131364A3
WO2008131364A3 PCT/US2008/061068 US2008061068W WO2008131364A3 WO 2008131364 A3 WO2008131364 A3 WO 2008131364A3 US 2008061068 W US2008061068 W US 2008061068W WO 2008131364 A3 WO2008131364 A3 WO 2008131364A3
Authority
WO
WIPO (PCT)
Prior art keywords
load
methods
disease
gab2
gene
Prior art date
Application number
PCT/US2008/061068
Other languages
French (fr)
Other versions
WO2008131364A2 (en
Inventor
Dietrich A Stephan
Eric M Reiman
Jennifer Webster
Christopher B Heward
Original Assignee
Translational Genomics Res Inst
Kronos Science Lab
Dietrich A Stephan
Eric M Reiman
Jennifer Webster
Christopher B Heward
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translational Genomics Res Inst, Kronos Science Lab, Dietrich A Stephan, Eric M Reiman, Jennifer Webster, Christopher B Heward filed Critical Translational Genomics Res Inst
Publication of WO2008131364A2 publication Critical patent/WO2008131364A2/en
Publication of WO2008131364A3 publication Critical patent/WO2008131364A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present disclosure relates to genetic markers and methods of diagnosing and screening for late-onset Alzheimer's disease (LOAD). As such, the disclosure encompasses a whole-genome association analysis of single nucleotide polymorphisms (SNPs) of which a number are located within the GRB2-associated binding protein 2 (GAB2) gene as well as other markers associated with other genes. The disclosure identifies two novel haplotypes within the GAB2 gene, i.e., a LOAD risk-enhancing and a LOAD risk-decreasing haplotype. These haplotypes modify LOAD risk differentially in combination with APOE alleles. Further encompassed are therapeutic methods and agents of decreasing the deterioration of cells associated with LOAD.
PCT/US2008/061068 2007-04-20 2008-04-21 Methods of diagnosing alzheimer's disease and associated markers WO2008131364A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92563807P 2007-04-20 2007-04-20
US60/925,638 2007-04-20
US93358207P 2007-06-06 2007-06-06
US60/933,582 2007-06-06

Publications (2)

Publication Number Publication Date
WO2008131364A2 WO2008131364A2 (en) 2008-10-30
WO2008131364A3 true WO2008131364A3 (en) 2009-02-12

Family

ID=39876185

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/061068 WO2008131364A2 (en) 2007-04-20 2008-04-21 Methods of diagnosing alzheimer's disease and associated markers

Country Status (1)

Country Link
WO (1) WO2008131364A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067512A1 (en) * 2001-11-09 2004-04-08 Neurogenetics, Inc. Single nucleotide polymorphisms and mutations on Alpha-2-Macroglobulin
US20040116682A1 (en) * 1998-03-06 2004-06-17 Nordine Cheikh Nucleic acid molecules and other molecules associated with the carbon assimilation pathway
US20050170399A1 (en) * 1996-05-23 2005-08-04 Stefan Somlo Polycystic kidney disease PKD2 gene and uses thereof
US20070054278A1 (en) * 2003-11-18 2007-03-08 Applera Corporation Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050170399A1 (en) * 1996-05-23 2005-08-04 Stefan Somlo Polycystic kidney disease PKD2 gene and uses thereof
US20040116682A1 (en) * 1998-03-06 2004-06-17 Nordine Cheikh Nucleic acid molecules and other molecules associated with the carbon assimilation pathway
US20040067512A1 (en) * 2001-11-09 2004-04-08 Neurogenetics, Inc. Single nucleotide polymorphisms and mutations on Alpha-2-Macroglobulin
US20070054278A1 (en) * 2003-11-18 2007-03-08 Applera Corporation Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAO ET AL.: "A novel role for Gab2 in bFGF-mediated cell survival during retinoic acid-induced neuronal differentiation", JOURNAL OF CELL BIOLOGY, vol. 170, 2005, pages 305 - 316 *
MISRA ET AL.: "Binding of receptor-recognized forms of alpha 2-macroglobulin to the alpha 2-macroglobulin signaling receptor activates phosphatidylinositol 3-kinase", JOURNAL BIOLOGICAL CHEMISTRY, vol. 273, 1998, pages 13399 - 13402 *

Also Published As

Publication number Publication date
WO2008131364A2 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
Birlea et al. Genome-wide association study of generalized vitiligo in an isolated European founder population identifies SMOC2, in close proximity to IDDM8
Duarte et al. Genome‐wide significant schizophrenia risk variation on chromosome 10q24 is associated with altered cis‐regulation of BORCS7, AS3MT, and NT5C2 in the human brain
MX2007015848A (en) Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitus.
Goto et al. Genetic analysis of typical wet-type age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese population
WO2006099259A3 (en) Novel missense mutations and single nucleotide polymorphisms in the rabphillin-3a-like gene and uses thereof
WO2006063704A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
Li et al. Loci with genome-wide associations with schizophrenia in the Han Chinese population
WO2007050794A3 (en) The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes
Koido et al. Polymorphisms in wolframin (WFS1) gene are possibly related to increased risk for mood disorders
WO2008131367A3 (en) Methods of diagnosing alzheimer's disease and markers identified by set association
Ning et al. Amyloid-β-related genes SORL1 and ACE are genetically associated with risk for late-onset Alzheimer disease in the Chinese population
EP3075865A3 (en) Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
Yuasa et al. Distribution of two Asian-related coding SNPs in the MC1R and OCA2 genes
Ide et al. Genetic and expression analyses of FZD3 in schizophrenia
Zeledón et al. Identification and functional studies of regulatory variants responsible for the association of NRG3 with a delusion phenotype in schizophrenia
WO2007120975A3 (en) Variants in complement regulatory genes predict age-related macular degeneration
Yuan et al. Angiotensinogen T174M and M235T variants and hypertension in the Hani and Yi minority groups of China
Gong et al. Association study of ACE polymorphisms and systemic lupus erythematosus in Northern Chinese Han population
WO2008131364A3 (en) Methods of diagnosing alzheimer's disease and associated markers
Bulut et al. Lack of association between catalase gene polymorphism (T/C exon 9) and susceptibility to vitiligo in a Turkish population
Tang et al. Case–control association study of the 2′, 3′-cyclic nucleotide 3′-phosphodiesterase (CNP) gene and schizophrenia in the Han Chinese population
WO2005123958A3 (en) Cd7 as biomarker and therapeutic target for psoriasis
Koga et al. Failure to confirm the association between the FEZ1 gene and schizophrenia in a Japanese population
WO2006063703A8 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2009137475A3 (en) Compositions and methods for diagnosing late-onset alzheimer's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08746478

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08746478

Country of ref document: EP

Kind code of ref document: A2